Earnings Call Summary | TELA Bio(TELA.US) Q3 2024 Earnings Conference
Earnings Call Summary | TELA Bio(TELA.US) Q3 2024 Earnings Conference
Operating loss improved to $9.4 million from $10.2 million in Q3 2023, and net loss improved to $10.4 million from $11 million.The following is a summary of the TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript:
以下是TELA Bio, Inc. (TELA) 2024年第三季度業績發佈會會議記錄的摘要:
Financial Performance:
財務表現：
TELA Bio reported Q3 2024 revenue of $19 million, reflecting a 26% year-over-year growth.
Gross margin for Q3 was at 68%, slightly down from 69% in the previous year, mainly due to higher charges for excess and obsolete inventory.
Operating loss improved to $9.4 million from $10.2 million in Q3 2023, and net loss improved to $10.4 million from $11 million.
Public offering added $43 million to the balance sheet, aiming for breakeven while sustaining growth.
TELA Bio報告了2024年第三季度營業收入爲1900萬，較去年同期增長了26%。
第三季度的毛利率爲68%，較去年同期的69%略有下降，主要是因爲過剩和過時庫存的費用增加。
運營虧損從2023年第三季度的1020萬改善爲940萬，淨虧損從1100萬改善爲1040萬。
公開募股爲資產負債表增加了4300萬，目標是在維持增長的同時實現盈虧平衡。
Business Progress:
業務進展：
TELA Bio experienced strong recovery and growth post-cybersecurity event impacts, with significant sales increases, particularly in Europe.
Marked the first $1 million sales month in Europe, showcasing successful market penetration.
Expanded product use in over 700 hospitals globally, with a focus on OviTex and OviTex PRS products.
Hosted influential industry events enhancing brand visibility and surgeon engagement.
Implemented sales force restructuring and enhanced training programs to improve productivity.
TELA Bio在經歷了網絡安全事件影響後實現了強勁的恢復和增長，尤其是在歐洲，銷售顯著增長。
在歐洲標誌着第一個100萬美元的銷售月，展示了成功的市場滲透。
在全球超過700家醫院擴展產品使用，重點是OviTex和OviTex PRS產品。
舉辦了影響力巨大的行業活動，提升品牌知名度並增強外科醫生參與度。
實施了銷售團隊重組並增強培訓項目，以提高生產力。
Opportunities:
機會：
Substantial growth in European markets with significant gains in U.K., Germany, and the Netherlands, driven by strategic initiatives aligning with Europe's patient consent models.
Recent public offering and operational optimizations positioned TELA for strong continued revenue growth and profitability, leveraging trends in natural repair and soft tissue preservation.
歐洲市場大幅增長，英國、德國和荷蘭獲得顯著收益，受益於與歐洲患者同意模型相一致的戰略舉措。
最近的公開募股和運營優化使TELA能夠強勁持續增長營業收入和盈利能力，利用自然修復和軟組織保存的趨勢。
Risks:
風險：
Anticipated operational changes for cost reduction might impact company dynamics and efficiency.
Potential disruptions in elective procedures due to external factors like natural disasters and market competition in tissue repair technologies.
預計的成本削減操作變化可能會影響公司的動態和效率。
由於自然災害和組織修復技術市場競爭等外部因素，計劃內手術可能會受到潛在干擾。
More details: TELA Bio IR
更多細節：TELA Bio投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更全面的細節，請參閱IR網站。 文章僅供投資者參考，不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
